Blood test for residual cancer in resectable pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial studies a blood test that looks for tiny traces of cancer-related DNA (called ctDNA) in people with pancreatic cancer that can be removed with surgery. The goal is to see whether this test can better predict how the cancer behaves and guide treatment decisions around surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed pancreatic cancer that is likely adenocarcinoma based on pathology or scan results
- Your cancer is considered resectable or borderline resectable (not spread beyond the pancreas)
- You are 18 or older
- Your day-to-day ability is good (ECOG 0 or 1)
- Your doctor plans either neoadjuvant chemo/chemo-radiation before surgery or surgery first
- You expect to live at least 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is studying a blood test that looks for tumor DNA (ctDNA) to see if it can help predict how well treatment is working in people with pancreatic cancer that hasn't spread. It is for patients getting chemotherapy before possible surgery.
This study tests whether a blood test that looks at DNA changes (ctDNA methylation) can help predict how pancreatic cancer will behave and guide treatment decisions. It includes people with suspected pancreatic cancer who are planning surgery or a biopsy.
This trial uses a blood test (ctDNA) to look for genetic material from tumors in patients with gastrointestinal cancers. It may help doctors understand and track your cancer better.
This study looks at DNA signals from blood tests (so-called “ctDNA” and another type of DNA test) in people with early-stage pancreatic cancer. It aims to see whether these tests can help track cancer after surgery and check for signs of return.
This trial is for people who had surgery for pancreatic cancer and are now deciding on maintenance therapy. A special blood test (ctDNA) may help doctors choose the best follow-up treatment to prevent the cancer from coming back.
This study looks at whether a special blood test (ctDNA) can detect tiny amounts of pancreatic cancer left after surgery. It may help doctors monitor who is at higher risk of cancer coming back, so they can tailor follow-up and treatment timing.
Hear when a new Pancreas Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.